Nektar Therapeutics (NKTR) Current Assets (2010 - 2026)

Nektar Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $589.0 million for Q1 2026.

• In Q1 2026, Current Assets rose 156.2% year-over-year to $589.0 million; the TTM figure through Mar 2026 stood at $589.0 million (up 156.2% YoY), while the FY2025 annual figure was $266.3 million, up 1.9% from the prior year.
• Current Assets for Q1 2026 stood at $589.0 million, up from $266.3 million in the prior quarter.
• The five-year high for Current Assets was $733.5 million in Q1 2022, with the low at $186.6 million in Q2 2025.
• The 5-year median for Current Assets is $330.7 million (2023), against an average of $407.2 million.
• The sharpest annual moves came in 2023 and 2026: Current Assets sank 39.43% in 2023, then jumped 156.2% in 2026.
• Nektar Therapeutics' Current Assets stood at $546.0 million in 2022, then tumbled by 39.43% to $330.7 million in 2023, then dropped by 20.99% to $261.3 million in 2024, then increased by 1.9% to $266.3 million in 2025, then surged by 121.22% to $589.0 million in 2026.
• Business Quant data shows NKTR's Current Assets at $589.0 million in Q1 2026, $266.3 million in Q4 2025, and $281.4 million in Q3 2025.